6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of May 2023

Commission File Number: 001-40413

Quipt Home Medical Corp.

(Translation of registrant’s name into English)

1019 Town Drive

Wilder, Kentucky 41076

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☐                Form 40-F  ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

EXHIBIT INDEX

Exhibit	Description
99.1	Condensed Consolidated Interim Financial Statements and notes thereto as at and for the three and six months ended March 31, 2023 and 2022
99.2	Management’s Discussion and Analysis for the three and six months ended March 31, 2023
99.3	Form 52-109F2 - Certification of Interim Filings (CEO) dated May 15, 2023
99.4	Form 52-109F2 - Certification of Interim Filings (CFO) dated May 15, 2023
99.5	News Release dated May 15, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Quipt Home Medical Corp.
Date: May 15, 2023	/s/ Gregory Crawford
	Chief Executive Officer

EX-99.1

Exhibit 99.1

Quipt Home Medical Corp.

Condensed Consolidated Interim Financial Statements

2023 Second Quarter

For the three and six months ended

March 31, 2023 and 2022

(UNAUDITED)

(Expressed in US Dollars)

TABLE OF CONTENTS

Condensed Consolidated Interim Statements of Financial Position	Page 1
Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss)	Page 2
Condensed Consolidated Interim Statements of Changes in Shareholders’ Equity	Page 3
Condensed Consolidated Interim Statements of Cash Flows	Page 4
Notes to the Condensed Consolidated Interim Financial Statements	Pages 5-16

Quipt Home Medical Corp.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(UNAUDITED)

(Expressed in thousands of US Dollars, except per share amounts)

		As at		As at
		March 31,		September 30,
	Notes	2023		2022
ASSETS
Current Assets
Cash		$	2,087	$	8,516
Accounts receivable, net	4		25,166		16,383
Inventory	5		20,377		15,585
Prepaid and other current assets			1,862		1,052
Total current assets			49,492		41,536
Long-term assets
Property, equipment, and right of use assets, net	6		52,042		33,497
Goodwill	7		50,725		28,208
Intangible assets, net	7		73,042		28,887
Other assets	10		242		86
Total long-term assets			176,051		90,678
TOTAL ASSETS		$	225,543	$	132,214
LIABILITIES
Current Liabilities
Accounts payable		$	23,433	$	13,841
Accrued liabilities			5,708		3,451
Current portion of equipment loans	10		11,365		5,473
Current portion of lease liabilities	10		4,330		3,304
Current portion of senior credit facility	10		16,048		6,857
Deferred revenue	9		4,396		3,036
Purchase price payable	3		2,890		5,778
Total current liabilities			68,170		41,740
Long-term Liabilities
Equipment loans	10		138		234
Lease liabilities	10		12,386		7,195
Senior credit facility	10		63,047		3,378
SBA Loan	10		—		120
TOTAL LIABILITIES			143,741		52,667
SHAREHOLDERS' EQUITY
Capital stock	11		219,206		214,254
Contributed surplus			24,045		26,317
Accumulated deficit			(161,449)		(161,024)
TOTAL SHAREHOLDERS' EQUITY			81,802		79,547
TOTAL LIABILITIES AND EQUITY		$	225,543	$	132,214

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page   1

Quipt Home Medical Corp.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF INCOME (LOSS) AND

COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(Expressed in thousands of US Dollars, except per share amounts)

		Three Months		Three Months		Six Months		Six Months
		Ended March 31,		Ended March 31,		Ended March 31,		Ended March 31,
	Notes	2023		2022		2023		2022
Revenue
Rentals of medical equipment		$	24,515	$	17,866	$	42,940	$	32,847
Sales of medical equipment and supplies			33,605		15,687		55,995		30,230
Total revenues			58,120		33,553		98,935		63,077
Cost of inventory sold			14,909		7,354		24,983		15,013
Operating expenses	13		27,686		16,256		47,148		29,670
Bad debt expense			2,482		3,167		4,765		5,579
Depreciation	6		8,127		4,992		14,120		9,558
Amortization of intangible assets	7		1,454		467		2,256		915
Stock-based compensation	11		1,306		1,161		1,877		3,271
Acquisition-related costs	3		900		4		1,157		66
Gain on disposal of property and equipment			(55)		(38)		(55)		(3)
Other income from government grant			—		(4,254)		—		(4,254)
Operating income			1,311		4,444		2,684		3,262
Financing expenses
Interest expense, net			2,022		487		2,734		986
Loss on foreign currency transactions			8		85		12		126
Loss on extinguishment of debt			30		—		30		—
Change in fair value of debentures			—		(1,319)		—		(1,058)
Income (loss) before taxes			(749)		5,191		(92)		3,208
Provision for income taxes	14		—		155		333		303
Net income (loss)		$	(749)	$	5,036	$	(425)	$	2,905
Net income (loss) per share	15
Basic earnings (loss) per share		$	(0.02)	$	0.15	$	(0.01)	$	0.09
Diluted earnings (loss) per share		$	(0.02)	$	0.14	$	(0.01)	$	0.08
Weighted average number of common shares outstanding:
Basic			35,858		33,438		36,117		33,393
Diluted			35,858		35,577		36,117		35,700

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page   2

Quipt Home Medical Corp. 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS’

EQUITY (UNAUDITED)

(Expressed in thousands of US Dollars, except per share amounts)

		Number of									Total
		Shares	Capital		Contributed		Shares to		Accumulated		shareholders'
	Notes	(000’s)	stock		surplus		be Issued		Deficit		equity
Balance September 30, 2021		33,350	$	202,827	$	21,001	$	657	$	(165,863)	$	58,622
Net income		—		—		—		—		2,905		2,905
Conversion of debentures		160		887		—		—		—		887
Stock options exercised	11	21		49		(24)		—		—		25
Stock-based compensation	11	—		—		3,271		—		—		3,271
Balance March 31, 2022		33,531	$	203,763	$	24,248	$	657	$	(162,958)	$	65,710
Balance September 30, 2022		35,605	$	214,254	$	26,317	$	—	$	(161,024)	$	79,547
Net loss		—		—		—		—		(425)		(425)
Acquisition of Great Elm	3	432		2,060		—		—		—		2,060
Settlement of restricted stock units	11	526		2,791		(4,129)		—		—		(1,338)
Exercise of options	11	50		101		(20)		—		—		81
Stock-based compensation	11	—		—		1,877		—		—		1,877
Balance March 31, 2023		36,613	$	219,206	$	24,045	$	—	$	(161,449)	$	81,802

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page   3

Quipt Home Medical Corp. 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (UNAUDITED)

(Expressed in thousands of US Dollars, except per share amounts)

		Six months		Six months
		ended March 31,		ended March 31,
	Notes	2023		2022
Operating activities
Net income (loss)		$	(425)		2,905
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	6, 7		16,376		10,473
Amortization of financing costs and accretion of purchase price payable	3, 10		266		93
Interest expense, net of amortization and accretion	10		2,468		893
Cash paid for interest			(2,441)		(914)
Loss on foreign currency transactions			12		126
Loss on fair value of convertible debentures	10		—		(1,058)
(Gain) loss on disposal of property and equipment			(55)		(3)
Loss on extinguishment of debt			30		—
Stock-based compensation	11		1,877		3,271
Other income from government grant			—		(4,254)
Adjustment to purchase price payable			50		—
Provision for income taxes			333		303
Cash paid for income taxes			(515)		(466)
Change in working capital (net of acquisitions):
Net (increase) decrease in accounts receivable			(3,252)		3
Net increase in inventory			(2,987)		(526)
Net (increase) decrease in prepaid and other current assets			(1,257)		559
Net increase (decrease) in deferred revenue			337		(117)
Net increase in accounts payables and accrued liabilities			3,999		533
Net cash flow provided by operating activities			14,816		11,821
Investing activities
Purchase of property and equipment	6		(4,937)		(3,683)
Cash proceeds from sale of property and equipment			26		227
Cash paid for acquisitions			(72,689)		(16,485)
Net cash flow used in investing activities			(77,600)		(19,941)
Financing activities
Repayments of loans	10		(6,623)		(6,174)
Repayments of leases	10		(1,953)		(1,689)
Issuance of debt under senior credit facility	10		70,000		—
Repayments of senior credit facility	10		(925)		—
Issuance costs related to senior credit facility	10		(439)		—
Payments of purchase price payable	3		(2,437)		(1,182)
Settlement of restricted stock units	11		(1,338)		—
Proceeds from exercise of options	11		81		24
Net cash flow provided by (used in) financing activities			56,366		(9,021)
Net decrease in cash			(6,418)		(17,141)
Effect of exchange rate changes on cash held in foreign currencies			(11)		(77)
Cash, beginning of period			8,516		34,612
Cash, end of period		$	2,087	$	17,394

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page   4

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

1. Nature of operations

Reporting entity

Quipt Home Medical Corp. (“Quipt” or the “Company”) was incorporated under the Business Corporations Act (Alberta) on March 5, 1993. On December 30, 2013, the Company was continued into British Columbia, Canada. The address of the registered office is 666 Burrard St, Vancouver, British Columbia, V6C 2Z7. The head office is located at 1019 Town Drive, Wilder, Kentucky, United States. The Company is a participating Medicare provider that provides i) nebulizers, oxygen concentrators, and CPAP (continuous positive airway pressure) and BiPAP (bi level positive air pressure) units; ii) traditional and non-traditional durable medical respiratory equipment and services; and iii) non-invasive ventilation equipment, supplies and services.

Basis of measurement

These consolidated financial statements have been prepared on a going concern basis that assumes that the Company will continue its operations for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of operations.

2. Summary of significant accounting policies

Statement of compliance

These unaudited condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34, “Interim Financial Reporting”, using accounting policies consistent with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. These condensed consolidated interim financial statements do not include all the disclosures required in annual consolidated financial statements and should be read in conjunction with the Company’s audited consolidated financial statements for the year ended September 30, 2022.

The Company has followed the same basis of presentation, accounting policies and method of computation for these condensed consolidated interim financial statements as disclosed in the annual audited consolidated financial statements for the year ended September 30, 2022.

The unaudited consolidated financial statements were approved and authorized for issue by the Board of Directors on May 15, 2023.

3. Business acquisitions

Acquisition of Great Elm Healthcare, LLC

On January 3, 2023, the Company, through one of its indirect wholly-owned subsidiaries, acquired Great Elm Healthcare, LLC (“Great Elm”). The purchase price was $74,749,000, which is comprised of approximately $72,689,000 in cash, and 431,996 Quipt common shares at a closing price per share of $4.77 for $2,060,000. The cash was obtained from the delayed draw term loan and revolving credit facility components of the Facility. The Company expensed $1,078,000 of professional fees in conjunction with the acquisition for the six months ended March 31, 2023.

Page   5

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

The pro forma revenues and net income for Great Elm for the six months ended March 31, 2023 as if the acquisition had occurred on October 1, 2022 was approximately $31,000,000 and $700,000, respectively, of which approximately $16,000,000 and $500,000 were recognized in the period from January 3, 2023 to March 31, 2023.

The fair value of the acquired assets and liabilities is provisional pending final valuations of the assets and liabilities and is as follows:

Cash	$	820
Accounts receivable		5,531
Inventory		925
Prepaid and other current assets		292
Property, equipment, and right of use assets		15,199
Goodwill		23,061
Intangible assets		46,410
Other assets		161
Accounts payable		(5,650)
Accrued liabilities		(3,918)
Deferred revenue		(1,022)
Equipment loans		(4,259)
Lease liabilities		(2,801)
Net assets acquired	$	74,749
Cash paid at closing	$	72,689
Equity issued at closing		2,060
Consideration paid or payable	$	74,749

The goodwill is attributable to expected synergies from the combining operations. All of the goodwill is deductible for income tax purposes.

Purchase Price Payable

The purchase price payable included on the statements of financial position consists of amounts related to prior period acquisitions. Below is the movement in purchase price payable for the six months ended March 31, 2023 and 2022, respectively:

	Amount
Balance September 30, 2021 (current $2,383, long-term $133)	$	2,516
Addition from acquisitions		2,082
Accretion of interest		23
Payments		(1,182)
Balance March 31, 2022 (current $3,306, long-term $133)	$	3,439
Balance September 30, 2022 (current $5,778, long-term $0)	$	5,778
Adjustments on prior acquisitions		(493)
Accretion of interest		42
Payments		(2,437)
Balance March 31, 2023 (current $2,890, long-term $0)	$	2,890

Page   6

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

Of the adjustments on prior acquisitions for the six months ended March 31, 2023, $543,000 was adjusted through goodwill and $50,000 was included in “Acquisition-related costs” on the condensed consolidated interim statements of income (loss).

4. Accounts Receivable

Accounts receivable represent amounts due from insurance companies and patients. As of March 31, 2023, the Company has approximately 12% of the Company’s receivables due from Medicare:

	As at		As at
	March 31, 2023		September 30, 2022
Gross receivable	$	34,818	$	27,122
Reserve for expected credit losses		(9,652)		(10,739)
Total	$	25,166	$	16,383

5. Inventory

The expense for slow-moving inventory is included within cost of inventory sold in the condensed consolidated statement of income (loss) and comprehensive income (loss).

	As at March 31,		As at September 30,
	2023		2022
Serialized	$	8,936	$	5,814
Non-serialized		11,524		9,854
Reserve for slow-moving		(83)		(83)
Total Inventory	$	20,377	$	15,585

6. Property and equipment and right of use assets

The property and equipment and right of use assets was comprised of the following:

	As at			As at
Cost	March 31, 2023		September 31, 2022
Property and equipment, net	$	34,769	$	22,750
Right of use assets, net		17,273		10,747
Total	$	52,042	$	33,497

Rental equipment transferred from inventory during the six months ended March 31, 2023 and 2022 was $12,518,000 and $8,063,000 respectively. For the six months ended March 31, 2023 and 2022, the Company obtained equipment loans (Note 10) of $8,010,000 and $4,381,000, respectively, with the balance of $4,508,000 and $3,682,000 paid in cash, respectively.

7. Goodwill and Intangible Assets

The following is the activity in goodwill and intangible assets for the six months ended March 31, 2023 and 2022:

Page   7

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

							Sub-total
							intangibles
			Customer		Other		with finite
Cost	Goodwill		relationships		Intangibles		lives		Total
Balance September 30, 2021	$	12,456	$	20,690	$	8,109	$	28,799	$	41,255
Acquisitions		13,543		—		—		—		13,543
Disposals		—		—		(2)		(2)		(2)
Balance March 31, 2022	$	25,999	$	20,690	$	8,107	$	28,797	$	54,796
Balance September 30, 2022	$	28,208		34,898		10,499	$	45,397	$	73,605
Acquisitions		23,061		40,590		5,820		46,410		69,471
Adjustments to prior year acquisitions		(544)		—		—		—		(544)
Balance March 31, 2023	$	50,725	$	75,488	$	16,319	$	91,807	$	142,532

							Sub-total
							intangibles
			Customer		Other		with finite
Accumulation amortization	Goodwill		relationships		Intangibles		lives		Total
Balance September 30, 2021	$	—	$	8,267	$	5,658	$	13,925	$	13,925
Amortization		—		729		186		915		915
Disposals		—		(2)		—		(2)		(2)
Balance March 31, 2022	$	—	$	8,994	$	5,844	$	14,838	$	14,838
Balance September 30, 2022	$	—	$	10,345	$	6,165	$	16,510	$	16,510
Amortization		—		1,797		458		2,256		2,256
Balance March 31, 2023	$	—	$	12,142	$	6,623	$	18,766	$	18,766

							Sub-total
							intangibles
			Customer		Other		with finite
Net carrying amount	Goodwill		relationships		Intangibles		lives		Total
Balance September 30, 2021	$	12,456	$	12,423	$	2,451	$	14,874	$	27,330
Balance March 31, 2022	$	25,999	$	11,696	$	2,263	$	13,959	$	39,958
Balance September 30, 2022	$	28,208	$	24,553	$	4,334	$	28,887	$	57,095
Balance March 31, 2023	$	50,725	$	63,346	$	9,696	$	73,042	$	123,767

8. Government Grant

During the year ended September 30, 2020, the Company received payments related to the US CARES Act.

Payroll Protection Plan (“PPP’)

During April 2020, the Company received $4,254,000 related to the PPP, which was to assist companies in maintaining their workforce. The loans and accrued interest were forgivable if the borrower uses the loan proceeds for eligible purposes. On March 23, 2022, the loan was forgiven, and “other income from government grant” was recorded in the condensed consolidated interim financial statements for the three and six months ended March 31, 2022. No balance remained on the balance sheet as of March 31, 2023 and September 30, 2022.

Page   8

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

9. Deferred Revenue

Activity for deferred revenue for the six months ended March 31, 2023 and 2022 is as follows:

	For the six			For the six
	months ended		months ended
	March 31, 2023		March 31, 2022
Beginning Balance	$	3,036	$	2,452
Acquisitions		1,022		202
Net change		338		(118)
Ending Balance	$	4,396	$	2,536

10. Long-term Debt

Senior Credit Facility

In September 2022, the Company entered into a five-year, $110,000,000 senior credit facility (“Facility”) with a group of US banks. The facility consists of a.) a delayed draw term loan facility of $85,000,000, of which $64,000,000 was drawn on January 3, 2023, to partially fund the acquisition of Great Elm, b.) a term loan of $5,000,000 that was drawn at closing, and c.) a $20,000,000 revolving credit facility. The Facility amended the $20,000,000 revolving credit facility that was entered into in September 2020. The Facility is secured by substantially all assets of the Company and is subject to certain financial covenants.  

The Facility bears interest at variable rates ranging in length from daily to three and six months and has fees for unused balances. As of March 31, 2023, the outstanding balances under the Facility totaled $81,075,000, comprised of $63,200,000 on the delayed draw term loan, $4,875,000 on the term loan, and $13,000,000 on the revolving credit facility.

As of March 31, 2023, the delayed draw term loan bears interest at 7.0% and is repayable in quarterly installments of $800,000, with the balance due at maturity. The term loan bears interest at an annual rate of 6.8% and is repayable in quarterly installments of $62,500, with the balance due at maturity. The revolving credit facility bears interest at an annual rate of 7.0% and is payable at maturity. It is classified as a current liability as it is expected to be repaid during the next twelve months.

Interest expense on the Facility was $1,407,000 and $1,620,000 for the three and six months ended March 31, 2023, respectively. The fair value of the facility approximates the carrying value as of March 31, 2023.

The Company has incurred $2,218,000 in financing costs to obtain the Facility, which is reflected as a reduction of the outstanding balance and will be amortized as interest expense using the effective interest method over the life of the Facility. During the three and six months ended March 31, 2023, $134,000 and $223,000 of amortization of deferred financing costs was recorded, respectively.

Page   9

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

A summary of the balances related to the Facility as of March 31, 2023 and September 30, 2022 is as follows:

	As of		As of
	March 31, 2023		September 30, 2022
Delayed-draw term loan	$	63,200	$	—
Term loan		4,875		5,000
Revolving credit facility		13,000		7,000
Total principal		81,075		12,000
Deferred financing costs		(1,980)		(1,765)
Net carrying value	$	79,095	$	10,235
Current portion		16,048		6,857
Long-term portion		63,047		3,378
Net carrying value	$	79,095	$	10,235

The revolving credit facility that was replaced with the Facility incurred interest expense of $12,000 and $25,000 for the three and six months ended March 31, 2022, respectively. Issuance costs were being amortized on a straight-line over the four-year term of the facility for a total of $35,000 and $70,000 for the three and six months ended March 31, 2022, respectively.

Debentures

On March 7, 2019, the Company issued C$15,000,000 in 8.0% Convertible Unsecured Debentures due March 7, 2024, with interest payable semi-annually on June 30 and March 31. Each C$1,000 (US$807) debenture was convertible at the option of the holder into 192.31 common shares. Beginning March 9, 2022, the Company could force conversion of the outstanding principal at a conversion price of C$5.20 per share, if the daily volume weighted average price of the common shares exceeds C$6.48 per share for twenty consecutive trading days. The Company exercised this option during the year ended September 30, 2022. No debentures remain outstanding as of March 31, 2023 or September 30, 2022.

The debentures contained multiple embedded derivatives including conversion right, forced conversion option and payment in lieu of common shares. Since the Company was unable to measure the fair value of embedded derivatives reliably, it had chosen to designate the convertible debentures in their entirety (including conversion right, forced conversion option and payment in lieu of common shares) to be subsequently measured at fair value through profit or loss (FVTPL). The debentures were valued at fair value using the current trading price, and a gain of $1,319,000 and $1,058,000 was recorded for the three and six months ended March 31, 2022, respectively.

Equipment Loans

The Company is offered financing arrangements from the Company’s suppliers and the suppliers’ designated financial institutions, under which payments for certain invoices or products can be financed and paid over an extended period. The financial institution pays the supplier when the original invoice becomes due, and the Company pays the third-party financial institution over a period of time. In most cases, the supplier accepts a discounted amount from the financial institution and the Company repays the financial institution the face amount of the invoice with no stated interest, in twelve equal monthly installments. The Company used an incremental borrowing rate of 6% - 7% to impute interest on these arrangements. There are no covenants with the loans and the carrying value of the equipment that is pledged as security against the loans is $20,318,000 and $14,949,000 as of March 31, 2023 and September 30, 2022, respectively.

Page   10

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

Following is the activity in equipment loans for the six months ended March 31, 2023 and 2022:

	Six months ended		Six months ended
	March 31, 2023		March 31, 2022
Beginning Balance	$	5,707	$	7,384
Additions:
Acquisitions		4,259		—
Operations		8,010		4,381
Repayments		(6,473)		(6,174)
Ending Balance		11,503		5,591
Current portion		11,365		5,351
Long-term portion	$	138	$	240

Leases Liabilities

The Company enters into leases for real estate and vehicles. Real estate leases are valued at the net present value of the future lease payments at an 8% incremental borrowing rate. Vehicle leases are recorded at rate implicit in the lease based on the current value and the estimated residual value of the vehicle, equating to rates ranging from 3.0% to 11.3%.

Following is the activity in lease liabilities for the six months ended March 31, 2023 and 2022:

			Real
	Vehicles		estate		Total
Balance September 30, 2021	$	2,414	$	5,351	$	7,765
Additions:
Acquisitions		571		1,443		2,014
Operations		241		517		758
Lease terminations		—		(78)		(78)
Repayments		(629)		(1,060)		(1,689)
Balance March 31, 2022	$	2,597	$	6,173	$	8,770
Balance September 30, 2022	$	1,993	$	8,506	$	10,499
Additions:
Acquisitions		365		2,436		2,801
Operations		497		4,872		5,369
Repayments		(368)		(1,585)		(1,953)
Balance March 31, 2023	$	2,487	$	14,229	$	16,716

Page   11

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

Future payments pursuant to lease liabilities are as follows:

	As at		As at
	March 31, 2023		September 30, 2022
Less than 1 year	$	5,522	$	3,979
Between 1 and 5 years		13,083		7,443
More than five years		1,323		1,108
Gross lease payments		19,928		12,530
Less: finance charges		(3,212)		(2,031)
Net lease liabilities		16,716		10,499
Current portion		4,330		3,304
Long-term portion	$	12,386	$	7,195

SBA Loan

In conjunction with an acquisition, the Company assumed an SBA Loan. The face amount of the loan was $150,000 and bears interest at a stated interest rate of 3.75%. Due to the below-market interest rate, the Company valued the loan at the net present value of the payments using the incremental borrowing rate of 6%, resulting in a fair value on the acquisition date of $119,000. The loan was payable in monthly principal and interest installments of $731 through May 2051 and is secured by substantially all the assets of the acquired subsidiary. The loan was paid off during the three and six months ended March 31, 2023, and a loss on extinguishment on approximately $30,000 was recorded in the condensed consolidated interim financial statements.

Following is the activity in the SBA Loan for the six months ended March 31, 2023 and 2022:

	Six months ended		Six months ended
	March 31, 2023		March 31, 2022
Beginning Balance	$	120	$	121
Loss on extinguishment		30		—
Repayments		(150)		—
Ending Balance	$	—	$	121

11. Share capital

The Company considers its capital to be shareholders’ equity, which is comprised of capital stock, contributed surplus, shares to be issued, and accumulated deficit, in the amount of $81,058,000 and $79,547,000 as at March 31, 2023 and September 30, 2022, respectively.

Issued share capital

The Company has only one class of common stock outstanding. Effective May 13, 2021, the Company consolidated its issued and outstanding common shares based on one post-consolidation common share for every four pre-consolidation common shares. Unless otherwise stated, the share, options and warrants along with corresponding exercise prices and per-share amounts have been restated retrospectively to reflect this share consolidation.

Common shares are classified as equity. Incremental costs directly attributable to the issuance of common shares are recognized as a reduction of equity, net of any income tax effects.  

Page   12

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

Shares to be issued

The Company acquired a company during the year ended September 30, 2021, with a portion of the purchase price payable in shares. The fair value of the stock had been discounted by 25%, using the Black-Scholes pricing model for put options, to reflect the inability to sell the stock for a period and for the time between the date of the acquisition and the dates the stock was to be issued. The shares that were scheduled to be issued in August 2022, were settled instead, upon mutual agreement of the parties, with a cash payment of $1,100,000 in the fourth quarter of fiscal year 2022.

Stock options and grants

The Company has a stock option plan, which it uses for grants to directors, officers, employees, and consultants. Options granted under the plan are non-assignable and may be granted for a term not exceeding ten years. Stock options having varying vesting periods and the options granted during the six months ended March 31, 2023 vest quarterly over eight or twelve quarters.

A summary of stock options is provided below:

		Weighted
	Number of options (000’s)	average exercise price
Balance September 30, 2021	3,786	C$	4.15
Issued	175		6.75
Exercised	(21)		1.50
Expired	(13)		5.89
Forfeited	(95)		8.48
Balance March 31, 2022	3,832	C$	4.16
Balance September 30, 2022	3,751	C$	4.24
Issued	435		8.30
Exercised	(50)		2.20
Expired	(36)		6.82
Forfeited	(46)		7.06
Balance March 31, 2023	4,054	C$	4.54

At March 31, 2023, the Company had 3,062,476 vested stock options with a weighted average exercise price of C$3.35.  

Restricted stock units

On May 20, 2021, 953,750 restricted stock units were granted to officers and directors. Each unit represents the right to ‎receive one common share, and vests over a period of two years from the grant date at the rate of one-eighth every three months commencing three months after the grant date. During the year ended September 30, 2022, 105,000 units were forfeited. On February 1, 2022, 81,340 restricted stock units were granted to officers. Each unit represents the right to ‎receive one common share and vested in four installments on the last day of each calendar quarter of 2022. The 645,313 units that vested in calendar years 2021 and 2022 were settled through the issuance of 526,193 shares during the three and six months ended March 31, 2023. The number of shares issued was less than the number of units settled due to the officers’ election to receive a reduced number of shares to satisfy their tax withholding obligations. These tax withholdings resulted in a cash outflow of $1,338,000 by the Company.

Page   13

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

On February 20, 2023, 831,000 restricted stock units were granted to officers and directors. Each unit represents the right to ‎receive one common share, and vests over a period of two years from the grant date at the rate of one-eighth every three months commencing three months after the grant date.

As of March 31, 2023, 1,034,438 restricted stock units were outstanding, of which 101,719 had vested.

The fair value of the restricted stock units on the date of grant are discounted to reflect the difference between the vesting dates and the expected issuance dates, to be expensed over the respective vesting periods with an increase to contributed surplus.

Stock-based compensation

The Company accounts for stock-based compensation using the fair value method as prescribed by IFRS 2. Under this method, the fair value of stock options and restricted stock units at the date of grant is expensed over the vesting period and the offsetting credit is recorded as an increase in contributed surplus. An estimate of the number of awards that are expected to be forfeited is also made at the time of grant and revised periodically if actual forfeitures differ from those estimates.

For the six months ended March 31, 2023 and 2022, the Company recorded stock-based compensation expense as follows:

	Three Months		Three Months		Six months		Six months
	Ended March 31,		Ended March 31,		Ended March 31,		Ended March 31,
	2023		2022		2023		2022
Restricted stock units	$	713	$	530		1,058		1,650
Stock options		593		631		819		1,621
Stock-based compensation expense	$	1,306	$	1,161	$	1,877	$	3,271

12. Commitments and contingencies

Commitments

The Company leases certain facilities with terms of less than a year that are classified as operating leases. Future payments pursuant to these leases are $76,000 as of March 31, 2023, which are all due in less than one year.

Contingencies

From time to time, the Company is involved in various legal proceedings arising from the ordinary course of business. None of the matters in which the Company is currently involved, either individually, or in the aggregate, is expected to have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows.

Page   14

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

13. Operating expenses

	Three months		Three months		Six months		Six months
	ended March 31,		ended March 31,		ended March 31,		ended March 31,
	2023		2022		2023		2022
Payroll and employee benefits	$	18,596	$	9,965	$	30,955	$	18,583
Facilities		1,408		897		2,453		1,497
Billing		2,322		1,458		4,201		2,846
Professional fees		758		1,335		1,750		1,970
Outbound freight		1,150		483		1,815		916
Vehicle fuel and maintenance		1,038		843		1,823		1,246
All other		2,414		1,275		4,151		2,612
Total operating expenses	$	27,686	$	16,256	$	47,148	$	29,670

14. Income taxes

As of March 31, 2023 and September 30, 2022, the Company's deferred tax liability was zero. Cumulative deferred tax assets are fully reserved as there is not sufficient evidence to conclude it is more likely than not the deferred tax assets are realizable. There is no current liability for federal income taxes. A state and local income tax payable of $64,000 and $246,000 as of March 31, 2023 and September 30, 2022, respectively, has been included within “Accrued liabilities” in the condensed consolidated interim statements of financial position. The provision for income taxes related to the state and local income taxes and was $0 and $333,000 for the three and six months ended March 31, 2023, respectively, and $155,000 and $303,000 for the three and six months ended March 31, 2022, respectively.

15. Income (loss) per share

Income (loss) per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share amounts are calculated giving effect to the potential dilution that would occur from the incremental shares issued if in-the-money securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and warrants are used to purchase common shares at the prevailing market price. For periods with a net loss, the potential dilutive shares were excluded because their effect is anti-dilutive.

The following reflects the earnings and share data used in the basic and diluted income (loss) per share computations:

	Three months		Three months		Six months		Six months
	ended March 31,		ended March 31,		ended March 31,		ended March 31,
	2023		2022		2023		2022
Net income (loss)	$	(749)	$	5,036	$	(425)	$	2,905
Basic weighted average number of shares		35,858		33,438		36,117		33,393
Diluted weighted average number of shares		35,858		35,577		36,117		35,700
Basic earnings (loss) per share	$	(0.02)	$	0.15	$	(0.01)	$	0.09
Diluted earnings (loss) per share	$	(0.02)	$	0.14	$	(0.01)	$	0.08

The effect of instruments exercisable or convertible to common shares for the three and six months ended March 31, 2023 were excluded from the calculation of diluted loss per share because their effect is anti-dilutive.

Page   15

Quipt Home Medical Corp. 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED) MARCH 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands of US Dollars, except per share amounts)

16. Related party transactions

The Company has six leases for office, warehouse, and retail space with a rental company affiliated with the Company’s Chief Executive Officer, the majority of which were entered into in 2015, five of which were renewed on October 1, 2022. The leases have a combined area of 74,520 square feet. Lease payments under these leases were approximately $65,000 and $52,000 per month for the six months ended March 31, 2023 and 2022, respectively, with increases on October 1 of each year equal to the greater of (i) the Consumer Price Index for All Urban Consumers (CPI-U), and (ii) 3%. One lease expires in June 2026 and the remaining five leases expire on September 30, 2029.

Expense for Board of Directors’ fees were $69,000 and $88,000 for the three months ended March 31, 2023 and 2022, respectively. Expense for Board of Directors’ fees were $156,000 and $128,000 for the six months ended March 31, 2023 and 2022, respectively. Stock-based compensation for the Board of Directors was $371,000 and $(341,000) for the three months ended March 31, 2023 and 2022, respectively. Stock-based compensation for the Board of Directors was $434,000 and $237,000 for the six months ended March 31, 2023 and 2022, respectively.

Key management personnel also participate in the Company’s share option program (see Note 1). The Company recorded compensation to key management personnel as follows:

	Three months		Three months		Six months		Six months
	ended March 31,		ended March 31,		ended March 31,		ended March 31,
	2023		2022		2023		2022
Salaries and benefits	$	256	$	244	$	547	$	511
Stock-based compensation		441		572		678		1,668
Total	$	697	$	816	$	1,225	$	2,179

17. Subsequent event

On April 25, 2023, the Company completed a bought deal public offering and brokered private placement. In connection therewith, the Company issued 5,409,000 common shares for aggregate gross proceeds of approximately C$42,500,000, or $31,200,000. Underwriters received a commission of approximately C$2,100,000, or $1,500,000, and other professional fees are estimated to be approximately $800,000, for net proceeds of approximately $28,900,000. A portion of the net proceeds have been used to fully pay down the revolver portion of the Senior Credit Facility.

Page   16

EX-99.2

Exhibit 99.2

’sDiscussion and Analysis
2nd Quarter 2023
Management’s Discussion and Analysis For the Three and Six Months Ended March 31, 2023	Quipt Home Medical Corp.

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

The following Management’s Discussion and Analysis (“MD&A”) of the financial condition and results of operations of Quipt Home Medical Corp. and its subsidiaries (“Quipt” or the “Company”), prepared as of May 15, 2023 and should be read in conjunction with the unaudited consolidated financial statements for the three and six months ended March 31, 2023, including the notes therein. These unaudited condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (“IAS”) 34, “Interim Financial Reporting”, using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). Unless otherwise specified, all financial data is presented in US dollars. The words “we”, “our”, “us”, “Company”, and “Quipt” refer to Quipt Home Medical Corp. and/or the management and employees of the Company.

Additional information on the Company is available for review on SEDAR at www.sedar.com. Such information is not considered a part of this MD&A.

Table of Contents

Page 2	Caution Regarding Forward-Looking Statements
Page 4	Selected Quarterly Information
Page 5	About Our Business and Operating Results
Page 6	Operating Results
Page 11	Financial Position
Page 15	Accounting and Disclosure Matters
Page 19	Financial Instruments and Risk Management
Page 20	Risk Factors

Page | 1

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This Management’s Discussion and Analysis (“MD&A”) contains certain “forward-looking information” within the meaning of Canadian securities legislation and “forward-looking ‎statements” within the meaning of applicable securities legislation, including the United States Private Securities ‎Litigation Reform Act of 1995 (collectively, “forward-looking statements”)‎. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are ‎based upon the current beliefs, expectations, and assumptions regarding the future of its business, ‎future plans and strategies, and other future conditions of Quipt Home Medical Corp. (the “Company” or “Quipt”). Forward-looking ‎statements can be identified by the words ‎such as “expect”, “likely”, “may”, “will”,, “would”, “could”, “should”, “continue”, “contemplate”, “intend”, or ‎‎”anticipate”, “believe”, “envision”, “estimate”, “expect”, “plan”, “predict”, “project”, “target”, “potential”, ‎‎”proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or ‎statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking ‎statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other ‎statements that are not statements of fact. Such forward-looking statements are made as of the date of this ‎MD&A.‎

Forward-looking statements in this MD&A therein include, but are not limited to, statements with respect to:‎ operating results; ‎profitability; ‎ financial condition and resources; ‎ anticipated needs for working capital; ‎ liquidity; ‎ capital resources; ‎capital expenditures;‎ milestones; ‎licensing milestones; ‎ information with respect to future growth and growth strategies; ‎ anticipated trends in the industry in with the Company operates; ‎ the Company’s future financing plans; ‎ timelines; ‎ currency fluctuations; ‎ government regulation; ‎ unanticipated expenses; ‎ commercial disputes or claims; ‎limitations on insurance coverage; ‎ availability and expectations regarding of cash flow to fund capital requirements;‎ the product offerings of the Company;‎ the competitive conditions of the industry;‎ the competitive and business strategies of the Company;‎ on-going implications of the novel coronavirus (“COVID-19”);‎ statements relating to the business and future activities of, and developments related to, the Company, ‎including such things as future business strategy, competitive strengths, goals, expansion and growth ‎of the Company’s business, operations and plans; and ‎other events or conditions that may occur in the future.‎

Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of the ‎Company’s management made in light of its experience and its perception of trends, current conditions and ‎expected developments, as well as other factors that management believes to be relevant and reasonable in the ‎circumstances at the date that such statements are made, but which may prove to be incorrect. The Company ‎believes that the assumptions and expectations reflected in such forward-looking statements are reasonable. The ‎material factors and assumptions used to develop the forward-looking statements contained in this MD&A, ‎without limitation:‎ the Company’s ability to successfully execute its growth strategies and business plan;‎ the ability to successfully identify strategic acquisitions;‎ the Company’s ability to realize anticipated benefits, synergies or generate revenue, profits or value from ‎its recent acquisitions into existing operations;‎ management’s perceptions of historical trends, current conditions and expected future developments;‎ the ability of the Company to take market share from competitors; ‎the Company’s ability to attract and retain skill staff;‎ market conditions and competition;‎ the products, services and technology offered by the Company’s competitors;‎ the Company’s ability to generate cash flow from operations the Company’s ability to keep pace with changing regulatory requirements;‎ ongoing ability to conduct business in the regulatory environments in which the Company operates and ‎may operate in the future;‎ that the Company’s ability to maintain strong business relationships with its suppliers, service provides and ‎other third parties will be maintained; ‎COVID-19 and recall related supply chain issues will be resolved within the near future;‎ the Company’s ability to fulfill prescriptions for services and products; ‎ the anticipated growth of the niche market of home equipment and monitoring; the anticipated increase in demand for various medical products and equipment;‎ demand and interest in the Company’s products and services; ‎the ability to deploy up front capital to purchase monitoring and treatment equipment; ‎anticipated and unanticipated costs; ‎ the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses;‎ the general economic, financial market, regulatory and political conditions in which the Company operates ‎and the absence of material adverse changes in the Company’s industry, regulatory

Page | 2

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

environmental or ‎the global economy; and other considerations that management believes to be appropriate in the circumstances.‎

Forward-looking statements speak only as at the date they are made and are based on information currently ‎available and on the then current expectations. Readers are cautioned that forward-‎looking statements are not based on historical facts but instead are based on ‎reasonable assumptions and estimates ‎of management of the Company at the time they were provided ‎or made and involve known and unknown risks, ‎uncertainties and other factors which may cause the ‎actual results, performance or achievements of the Company, ‎as applicable, to be materially different ‎from any future results, performance or achievements expressed or implied ‎by such forward-looking ‎statements, including, but not limited to, known and unknown risks, uncertainties, ‎assumptions and other factors, including those listed under “Risk Factors”, which include: credit risks, market risks ‎‎(including those related to equity, commodity, foreign exchange and interest rate markets), liquidity risks, ‎operational risks (including those related to technology and infrastructure), and risks relating to reputation, ‎insurance, strategy, regulatory matters, legal matters, environmental matters and capital adequacy. Examples of ‎such risk factors include: the Company may be subject to significant capital requirements and operating risks; ‎changes in law, the ability to implement business strategies, growth strategies and pursue business opportunities; ‎state of the capital markets; the availability of funds and resources to pursue operations; decline of reimbursement ‎rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key ‎suppliers; granting of permits and licenses in a highly regulated business; competition; difficulty integrating newly ‎acquired businesses; low profit market segments; disruptions in or attacks (including cyber-attacks) on information ‎technology, internet, network access or other voice or data communications systems or services; the evolution of ‎various types of fraud or other criminal behavior; the failure of third parties to comply with their obligations; the ‎impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation ‎environment, including in the United States; risks related to ‎infectious ‎diseases, including the impacts of COVID-19; ‎increased competition; changes in foreign currency rates; loss of foreign private issuer status; risks relating to the ‎deterioration of global economic conditions; increased funding costs and market volatility due to market illiquidity ‎and competition for funding; critical accounting estimates and changes to accounting standards, policies, and ‎methods; and the occurrence of natural and unnatural catastrophic events and claims resulting from such events, ‎as well as other general economic, market and business conditions, amongst others, ‎as well as those risk factors ‎described under the heading “Risk Factors” and elsewhere in this MD&A  and therein and as described from time to time in documents filed by ‎the Company with Canadian securities regulatory authorities including, without limitation, the Company’s audited annual financial statements and the Company’s Annual Information Form (“AIF”). Although the Company has attempted to identify ‎important factors that could cause actual actions, events or results to differ materially from those described in ‎forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, ‎estimated or intended. The Company provides no assurance that forward-looking statements will prove to be ‎accurate, as actual results and future events could differ materially from those anticipated in such statements.‎

Readers are cautioned that the above list of cautionary statements is not exhaustive. A number of factors could ‎cause actual events, performance or results to differ materially from what is projected in forward-looking ‎statements. The purpose of forward-looking statements is to provide the reader with a description of management’s ‎expectations, and such forward-looking statements may not be appropriate for any other purpose. You should not ‎place undue reliance on forward-looking statements contained in this MD&A. Although the Company believes that the expectations ‎reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will ‎prove to have been correct. The Company undertakes no obligation to update or revise any forward-looking ‎statements, whether as a result of new information, future events or otherwise, except as required by applicable law. ‎The forward-looking statements contained in this MD&A are expressly qualified in their entirety by this cautionary statement. ‎

Page | 3

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

SECOND QUARTER 2023 HIGHLIGHTS

● On January 3, 2023, closed on the acquisition of Great Elm Healthcare, LLC (“Great Elm”), which is expected to add approximately $60 million of annual revenue.

● Increased revenues for the six months ended March 31, 2023 to $98.9 million, or 56.8%, from the six months ended March 31, 2022.

● Increased the number of equipment set-ups to 344,451 for the six months ended March 31, 2023 from 239,438 in the prior year period, an increase of 43.9%.

● Increased the number of respiratory resupply set-ups to 175,968 for the six months ended March 31, 2023 from 101,850 in the prior year period, an increase of 72.8%.

● Generated Adjusted EBITDA of $22.1 million for the six months ended March 31, 2023, a 69.3% increase from the prior year period, and represented 22.3% of revenue. Adjusted EBITDA is a non-IFRS measure and is reconciled to net income (loss) on page 7.

● On April 25, 2023, completed a public offering, generating approximately $28,900,000 of net proceeds.

SELECTED QUARTERLY INFORMATION

	For the three		For the three		For the six		For the six
	months		months		months		months
	ended March 31,		ended March 31,		ended March 31,		ended March 31,
	2023		2022		2023		2022
Number of patients serviced(1)		137,748		78,273		186,710		115,299
Number of equipment set-ups or deliveries		198,101		118,878		344,451		239,438
Respiratory resupply set-ups or deliveries		106,486		50,713		175,968		101,850
Total revenues	$	58,120	$	33,553	$	98,935	$	63,077
Net income (loss)	$	(749)	$	5,036	$	(425)	$	2,905
Adjusted EBITDA(2)	$	13,098	$	7,047	$	22,094	$	13,051
Basic earnings (loss) per share	$	(0.02)	$	0.15	$	(0.01)	$	0.09
Diluted earnings (loss) per share	$	(0.02)	$	0.14	$	(0.01)	$	0.08
Total assets					$	225,543	$	110,526
Total long-term liabilities					$	75,571	$	16,301
Shareholders' equity					$	81,802	$	65,710

(1) The six-month periods do not equal the sum of the two respective three-month periods due to some patients being serviced in multiple three-month periods.

(2) Refer to page six for definition of Adjusted earnings before interest, taxes, depreciation, and amortization (“EBITDA”)

The words “we”, “our”, “us”, “Company”, and “Quipt” refer to Quipt Home Medical Corp. and/or the management and employees of the Company.

Page | 4

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

Reporting entity

The Company’s shares are traded on the TSX Venture Exchange and on NASDAQ in the United States, both under the symbol QIPT.

ABOUT OUR BUSINESS

Quipt business objective

The growth in the number of elderly patients in the US healthcare market is creating pressure to provide more efficient delivery systems. Healthcare providers, such as hospitals, physicians, and pharmacies, are seeking partners that can offer a range of products and services that improve outcomes, reduce hospital readmissions, and help control costs. Quipt fills this need by delivering a growing number of specialized products and services to achieve these goals. Quipt seeks to provide an ever-expanding line of products and services over larger geographic regions within the United States using several growth strategies. With over 100 offices, Quipt employs more than 1,100 personnel in the United States.

Future outlook

Quipt expects to generate net profit and positive Adjusted EBITDA. Our top priority continues to be the generation of operational net profit, positive cash flow, and growth in EBITDA in fiscal year 2023 and beyond. As we continue to expand in our existing markets, we plan to leverage our business platforms to enter new markets. As we continue to grow and achieve scale, the increasing cash generated from operations will be used to market our products and services and to gain market share. Our continued integration and rationalization, and our acquisitions, have given us a focus and path towards profitability at each business unit.

Going forward, we seek to find ways to continue to grow our customer base and penetrate these markets, while continuing to streamline our operational platform and generate positive cash flow and operational profits. We will continue to improve on operational efficiencies and call center management as they are key execution points to maintaining our healthy gross margin while growing revenues by cross selling services to existing and acquired patients.

COVID-19 Pandemic  

In March 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic. The crisis related to COVID-19 is unprecedented and has had an impact on the Company's employees, customers, and suppliers in 2021 through 2023.

Supply Chain

The Company closely monitors the changing global environment to enable immediate actions to be taken to ensure customer order fulfillment is achieved across the various markets. The shipment of goods from Asia continues to be impacted by COVID-19 disruptions to manufacturing. Global chip shortages continue to impact parts of our business as well.

Demand

Consumer demand for Quipt products and services is strong in most major markets. Brick and mortar retail consumer traffic continues to be affected in some markets with government-imposed restrictions and consumer purchasing behavior. Online and e-commerce channels are active in the United States.

Page | 5

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

The demand for Quipt products and services were not adversely impacted by COVID-19. Demand for healthcare products and services increased during the pandemic as hospitals, physicians and pharmacies had an increased need to healthcare products and services, especially products and services relating to respiratory health and assistance.

OPERATING RESULTS

Accounting policies and estimates

The unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34, “Interim Financial Reporting” issued by the governing body of the IASB. The preparation of consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities, and the reported amounts of revenues and expenses for the period of consolidated financial statements.

Non-IFRS measures

Throughout this MD&A, references are made to several measures which are believed to be meaningful in the assessment of the Company’s performance. These metrics are non-standard measures under IFRS and may not be identical to similar measures reported by other companies. Readers are cautioned that the disclosure of these items is meant to add to, and not replace, the discussion of financial results as determined in accordance with IFRS. The primary purpose of these non-IFRS measures is to provide supplemental information that may prove useful to investors who wish to consider the impact of certain non-cash or uncontrollable items on the Company’s operating performance.

EBITDA and Adjusted EBITDA

In calculating EBITDA and Adjusted EBITDA, certain items are excluded from net income (loss), including interest, income taxes, depreciation, amortization, change in fair value of derivative financial liabilities, and stock-based compensation. Set forth below are descriptions of the financial items that have been excluded from net income or loss to calculate EBITDA and Adjusted EBITDA and the material limitations associated with using these non-IFRS financial measures as compared to net income or loss.

● Depreciation and amortization expense may be useful for investors to consider because they generally represent the wear and tear on our property and equipment used in our operations and amortization of intangibles valued in acquisitions. However, we do not believe these charges necessarily reflect the current and ongoing cash charges related to our operating costs.

● The amount of interest expense we incur or interest income we generate may be useful for investors to consider and may result in current cash inflows or outflows. However, we do not consider the amount of interest expense to be a representative component of the day-to-day operating performance of our business.

● The change in fair value of derivative financial liabilities is the change in value of the debenture and these changes are non-cash until realized upon settlement of the instruments.

● Income tax expense may be useful for investors to consider because it generally represents the taxes which may be payable for the period and may reduce the amount of funds otherwise available for use. However, we do not consider the amount of income tax expense to be a representative component of the day-to-day operating performance of our business.

Page | 6

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

● Stock-based compensation may be useful for investors to consider because it is an estimate of the non-cash component of compensation received by the Company’s directors, officers, employees, and consultants. However, stock-based compensation is being excluded from the Company’s operating expenses because the decisions which gave rise to these expenses were not made to increase revenue in a particular period but were made for the Company’s long-term benefit over multiple periods. While strategic decisions, such as those to issue stock-based awards are made to further the Company’s long-term strategic objectives and impact the Company’s earnings under IFRS, these items affect multiple periods and management is not able to change or affect these items within any period.

● Acquisition-related costs may be useful for the investors to consider because they are professional fees directly related to completing the various acquisitions. While the costs are expected to be recurring if the Company continues to make acquisitions, they are non-recurring as they relate to the specific acquisition and are incurred prior to the inclusion of such acquisitions in the consolidated revenues of the Company. Management uses both IFRS and non-IFRS measures when planning, monitoring, and evaluating the Company’s performance.

Page | 7

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

	Three		Three		Six		Six
	months		months		months		months
	ended March		ended March		ended March		ended March
	31, 2023		31, 2022		31, 2023		31, 2022
Net income (loss)	$	(749)	$	5,036	$	(425)	$	2,905
Add back:
Depreciation and amortization		9,581		5,459		16,376		10,473
Interest expense, net		2,022		487		2,734		986
Provision for income taxes		—		155		333		303
EBITDA		10,854		11,137		19,018		14,667
Stock-based compensation		1,306		1,161		1,877		3,271
Acquisition-related costs		900		237		1,157		299
Loss on foreign currency transactions		8		85		12		126
Loss on extinguishment of debt		30		—		30		—
Other income from government grant		—		(4,254)		—		(4,254)
Change in fair value of debentures and warrants		—		(1,319)		—		(1,058)
Adjusted EBITDA	$	13,098	$	7,047	$	22,094	$	13,051

This quarterly Adjusted EBITDA multiplied by four equates to annualized Adjusted EBITDA of $52,392,000, which surpasses the previously announced outlook of $49,000,000.

The following is a summary of the Company’s unaudited operating results as recorded in accordance with IFRS.

	Three months		Three months		Six months		Six months
	ended March 31,		ended March 31,		ended March 31,		ended March 31,
	2023		2022		2023		2022
Revenues	$	58,120	$	33,553	$	98,935	$	63,077
Inventory sold		14,909		7,354		24,983		15,013
Operating expenses		27,686		16,256		47,148		29,670
Bad debt expense		2,482		3,167		4,765		5,579
Depreciation		8,127		4,992		14,120		9,558
Amortization of intangible assets		1,454		467		2,256		915
Stock-based compensation		1,306		1,161		1,877		3,271
Acquisition related costs		900		4		1,157		66
Gain on disposals of property and equipment		(55)		(38)		(55)		(3)
Interest expense, net		2,022		487		2,734		986
Other income from government grant		—		(4,254)		—		(4,254)
Loss on foreign currency transactions		8		85		12		126
Loss on extinguishment of debt		30		—		30		—
Change in fair value of debentures		—		(1,319)		—		(1,058)
Provision for income taxes		—		155		333		303
Net income (loss)	$	(749)	$	5,036	$	(425)	$	2,905
Income (loss) per share
Basic	$	(0.02)	$	0.15	$	(0.01)	$	0.09
Diluted	$	(0.02)	$	0.14	$	(0.01)	$	0.08

Page | 8

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

Revenue

For the three months ended March 31, 2023, revenue totaled $58,120,000, an increase of $24,567,000, or 73.2%, from the three months ended March 31, 2022. This increase is primarily due to $16,000,000 from the acquisition of Great Elm during the three months ended March 31, 2023, with organic growth and the other acquisitions during the year ended September 30, 2022 also contributing. This quarterly revenue multiplied by four equates to annualized revenue of $232,480,000, which surpasses the previously announced outlook of $220,000,000.

For the six months ended March 31, 2023, revenue totaled $98,935,000, an increase of $35,858,000, or 56.8%, from the six months ended March 31, 2022. This increase is primarily due to approximately $33,000,000 from acquisitions during the three months ended March 31, 2023 and the year ended September 30, 2022, with organic growth also contributing.

Inventory sold

For the three months ended March 31, 2023, inventory sold totaled $14,909,000 as compared to $7,354,000 for the three months ended March 31, 2022. The increase in dollars was due to the growth in revenues. The increase as a percent of revenues was due to the higher mix of sales relative to rental revenues.

For the six months ended March 31, 2023, inventory sold totaled $24,983,000 as compared to $15,013,000 for the six months ended March 31, 2022. The increase in dollars was due to the growth in revenues. The increase as a percent of revenues was due to the higher mix of sales relative to rental revenues.

Operating expenses

For the three months ended March 31, 2023, operating expenses were $27,686,000, an increase of $11,430,000 from $16,256,000 for the three months ended March 31, 2022. Acquisitions contributed approximately $10,571,000 of the increase.

For the six months ended March 31, 2023, operating expenses were $47,148,000, an increase of $17,478,000 from $29,670,000 for the six months ended March 31, 2022. Acquisitions contributed approximately $15,498,000 of the increase. Remaining increases related to payroll.

Bad debt expense

Bad debt expense decreased by $685,000 to $2,482,000 for the three months ended March 31, 2023. This decrease is due to improved collections.

Bad debt expense decreased by $814,000 to $4,765,000 for the six months ended March 31, 2023. This decrease is due to improved collections.

Depreciation expense

Depreciation expense increased by $3,135,000 to $8,127,000 for the three months ended March 31, 2023. This increase is primarily due to the acquisitions during the three months ended March 31, 2023 and the year ended September 30, 2022.

Depreciation expense increased by $4,562,000 to $14,120,000 for the six months ended March 31, 2023. This increase is primarily due to the acquisitions during the three months ended March 31, 2023 and the year ended September 30, 2022.

Page | 9

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

Stock-based compensation

Stock-based compensation increased to $1,306,000 for the three months ended March 31, 2023 from $1,161,000 for the three months ended March 31, 2022, due to the grants of stock-based awards during the three months ended March 31, 2023.

Stock-based compensation decreased to $1,877,000 for the six months ended March 31, 2023 from $3,271,000 for the six months ended March 31, 2022, due to fewer stock-based awards from prior years remaining to be vested.

Interest expense

Interest expense for the three months ended March 31, 2023 increased to $2,022,000 from $487,000 for the three months ended March 31, 2022. This increase is due to higher borrowings on the Company’s Senior Credit facility as a result of the acquisition of Great Elm. There was also higher interest from a higher balance of real estate leases outstanding. These increases were partially offset by the decrease in interest expense related to the debentures that were converted to common shares in September 2022.

Interest expense for the six months ended March 31, 2023 increased to $2,734,000 from $986,000 for the six months ended March 31, 2022. This increase is due to higher borrowings on the Company’s Senior Credit facility as a result of the acquisition of Great Elm. There was also higher interest from a higher balance of real estate leases outstanding. These increases were partially offset by the decrease in interest expense related to the debentures that were converted to common shares in September 2022.

Change in fair value of debentures

Debentures issued during 2019 were valued at fair value using the current trading price. The change in fair value of debentures was a gain of $1,319,000 and $1,058,000 for the three and six months ended March 31, 2022, respectively. The debentures were converted to common stock during September 2022, so no debentures were outstanding during the three and six months ended March 31, 2023 to generate a change in fair value.

Provision for income taxes

The provision for incomes taxes related to state and local income taxes payable and was $0 and $155,000 for the three months ended March 31, 2023 and 2022, respectively.

The provision for incomes taxes related to state and local income taxes payable and was $333,000 and $303,000 for the six months ended March 31, 2023 and 2022, respectively.

Page | 10

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

FINANCIAL POSITION

	As at		As at
	March 31, 2023		September 30, 2022
Cash	$	2,087	$	8,516
Accounts receivable, inventory and prepaid assets		47,405		33,020
Property and equipment		52,042		33,497
Other assets		124,009		57,181
Total assets	$	225,543	$	132,214
Accounts payable and other current liabilities	$	68,170	$	41,740
Long-term debt and other long-term liabilities		75,571		10,927
Total liabilities		143,741		52,667
Shareholders’ equity		81,802		79,547
Total liabilities and shareholders’ equity	$	225,543	$	132,214

Liquidity

The Company’s primary source of liquidity is cash flow from operations and its line of credit availability.

Cash flows from operations could be negatively impacted by decreased demand for the Company’s products, which may result from factors such as adverse economic conditions and changes in public and consumer preferences, the loss of confidence by the Company’s principal customers in the Company and its product lines, or by increased costs associated with manufacturing and distribution of products. The Company expects that cash, future operating cash flows, and the amounts available to be drawn against the credit facilities will enable the Company to finance its capital investment program and fund its ongoing business requirements over the next twelve months, including working capital and financial obligations.

As of March 31, 2023, the Company had cash on hand of $2,087,000 and line of credit availability of $7,000,000. The Company’s approach in managing liquidity is to ensure, to the extent possible, that it will have enough liquidity to meet its liabilities when due. The Company will do so by continuously monitoring actual and expected cash flows and monitoring financial market conditions for signs of weakness. On April 25, 2023, the Company completed a bought deal public offering and brokered private placement for aggregate gross proceeds of approximately C$42,500,000, or $31,200,000. Underwriters received a commission of approximately C$2,100,000, or $1,500,000, and other professional fees are estimated to be approximately $800,000, for net proceeds of approximately $28,900,000, which significantly increased the Company’s liquidity. The net proceeds will be used to pay down the revolver portion of the Senior Credit Facility, potential future acquisitions, working capital, and general corporate purposes.

Capital management

The Company considers its capital to be shareholders’ equity, which is comprised of share capital, contributed surplus, and accumulated deficit, which totaled $81,802,000 at March 31, 2023, along with long-term debt, which totaled $75,571,000 at March 31, 2023.

The Company raises capital, as necessary, to meet its needs and take advantage of perceived opportunities and, therefore, does not have a numeric target for its capital structure. Funds are primarily obtained through the issuance of equity and debt instruments. On April 25, 2023, the Company completed a bought deal public offering and brokered private placement and issued 5,409,000 shares for aggregate gross proceeds of approximately C$42,500,000, or $31,200,000. Underwriters received a commission of approximately C$2,100,000, or $1,500,000, and other professional fees are estimated to be approximately $800,000, for net proceeds of approximately $28,900,000. The net proceeds will be used to pay down the revolver portion of the Senior Credit Facility, potential future acquisitions, working capital, and general corporate purposes.

Page | 11

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

The Company maintains all capital that is surplus to its immediate operational needs in cash with major US and Canadian financial institutions.

The Company had the following equity instruments outstanding at March 31, 2023 and September 30, 2022:

	As at	As at
	March 31, 2023	September 30, 2022
	(000’s)	(000’s)
Common shares	36,613	35,605
Options	4,054	3,751
Restricted stock units	1,058	930

The outstanding shares as of May 15, 2023 are 42,072,469 common shares, with the increase from March 31, 2023 primarily due to the completion of the bought deal public offering and brokered private placement on April 25, 2023.

Financing

Historically and currently, the Company has financed its operations primarily from cash flow from operations, equipment loans, leases, issuances of equity for cash, credit facilities, and through the issuance of shares to acquire businesses.

Senior Credit Facility

In September 2022, the Company entered into a five-year, $110,000,000 senior credit facility (“Facility”) with a group of US banks. The facility consists of a.) a delayed draw term loan facility of $85,000,000, of which $64,000,000 was drawn on January 3, 2023, to partially fund the acquisition of Great Elm, b.) a term loan of $5,000,000 that was drawn at closing, and c.) a $20,000,000 revolving credit facility. The facility amended the $20,000,000 revolving credit facility that was entered into in September 2020. The Facility is secured by substantially all assets of the Company and is subject to certain financial covenants.  

The Facility bears interest at variable rates ranging in length from daily to three and six months and has fees for unused balances. As of March 31, 2023, the outstanding balances under the Facility totaled $81,075,000, comprised of $63,200,000 on the delayed draw term loan, $4,875,000 on the term loan, and $13,000,000 on the revolving credit facility.

As of March 31, 2023, the delayed draw term loan bears interest at 7.0% and is repayable in quarterly installments of $800,000, with the balance due at maturity. The term loan bears interest at an annual rate of 6.8% and is repayable in quarterly installments of $62,500, with the balance due at maturity. The revolving credit facility bears interest at an annual rate of 7.0% and is payable at maturity. It is classified as a current liability as it is expected to be repaid during the next twelve months.

Interest expense on the Facility was $1,407,000 and $1,620,000 for the three and six months ended March 31, 2023, respectively. The fair value of the facility approximates the carrying value as of March 31, 2023.

The Company has incurred $2,218,000 in financing costs to obtain the Facility, which is reflected as a reduction of the outstanding balance and will be amortized as interest expense using the effective interest method over the life of the Facility. During the three and six months ended March 31, 2023, $134,000 and $223,000 of amortization of deferred financing costs was recorded, respectively.

A summary of the balances related to the Facility as of March 31, 2023 is as follows:

Page | 12

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

	As of		As of
	March 31, 2023		September 30, 2022
Delayed-draw term loan	$	63,200	$	—
Term loan		4,875		5,000
Revolving credit facility		13,000		7,000
Total principal		81,075		12,000
Deferred financing costs		(1,980)		(1,765)
Net carrying value	$	79,095	$	10,235
Current portion		16,048		6,857
Long-term portion		63,047		3,378
Net carrying value	$	79,095	$	10,235

Equipment Loans

The Company is offered financing arrangements from the Company’s suppliers and the suppliers’ designated financial institutions, under which payments for certain invoices or products can be financed and paid over an extended period. The financial institution pays the supplier when the original invoice becomes due, and the Company pays the third-party financial institution over a period of time. In most cases, the supplier accepts a discounted amount from the financial institution and the Company repays the financial institution the face amount of the invoice with no stated interest, in twelve equal monthly installments. The Company used an incremental borrowing rate of 6% - 7% to impute interest on these arrangements. Future payments on these liabilities as of March 31, 2023 are as follows:

Less than 1 year	$	11,531
Between 1 and 5 years		205
Total	$	11,736
Less: finance charges		(233)
Net lease liabilities		11,503
Current portion		11,365
Long-term portion	$	138

Lease Liabilities

The Company enters into leases for real estate and vehicles. Real estate leases are valued at the net present value of the future lease payments at an 8% incremental borrowing rate. Vehicle leases are recorded at rate implicit in the lease based on the current value and the estimated residual value of the vehicle, equating to rates ranging from 3.0% to 11.3%. Future payments on these liabilities are as follows:

Less than 1 year	$	5,522
Between 1 and 5 years		13,083
More than 5 years		1,323
Total		19,928
Less: finance charges		(3,212)
Lease liabilities		16,716
Current portion		4,330
Long-term portion	$	12,386

Page | 13

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

Contingencies

From time to time, the Company is involved in various legal proceedings arising from the ordinary course of business. None of the matters in which the Company is currently involved, either individually, or in the aggregate, is expected to have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows.

Quarterly operating results

	Quarter ended		Quarter ended		Quarter ended		Quarter ended
	Mar. 31, 2023		Dec. 31, 2022		Sep. 30, 2022		Jun. 30, 2022
Revenues	$	58,120	$	40,815	$	40,092	$	36,692
Net income (loss)		(749)		325		1,770		163
Net income (loss) per share - basic		(0.02)		0.01		0.05		0.00
Net income (loss) per share - diluted		(0.02)		0.01		0.05		0.00
Total assets	$	225,543	$	131,725	$	132,214	$	130,478

	Quarter ended		Quarter ended		Quarter ended		Quarter ended
	Mar. 31, 2022		Dec. 31, 2021		Sep. 30, 2021		Jun. 30, 2021
Revenues	$	33,553	$	29,525	$	29,118	$	26,238
Net income (loss)		5,037		(2,131)		(1,379)		6,329
Net income (loss) per share - basic		0.15		(0.06)		(0.04)		0.23
Net income (loss) per share - diluted		0.14		(0.06)		(0.04)		0.23
Total assets	$	110,526	$	107,376	$	108,573	$	106,542

Results of operations for the healthcare services market in which the Company operates show little seasonality from quarter to quarter. The increase in revenues from the past year is primarily due to the Company’s acquisitions. The volatility of the net income (loss) is primarily due to the change in fair value of debentures and warrants. In the three months ended March 31, 2022 and September 30, 2022, there was also income from government grants.

Related party transactions

The Company has six leases for office, warehouse, and retail space with a rental company affiliated with the Company’s Chief Executive Officer, the majority of which were entered into in 2015. The leases have a combined area of 74,520 square feet. Lease payments under these leases were approximately $65,000 and $52,000 per month for the six months ended March 31, 2023 and 2022, respectively, with increases on October 1 of each year equal to the greater of (i) the Consumer Price Index for All Urban Consumers (CPI-U), and (ii) 3%. One lease expires in June 2026 and the remaining five leases expire on September 30, 2029.

Expense for Board of Directors’ fees were $69,000 and $88,000 for the three months ended March 31, 2023 and 2022, respectively. Expense for Board of Directors’ fees were $156,000 and $128,000 for the six months ended March 31, 2023 and 2022, respectively. Stock-based compensation for the Board of Directors was $371,000 and $(341,000) for the three months ended March 31, 2023 and 2022, respectively. Stock-based compensation for the Board of Directors was $434,000 and $237,000 for the six months ended March 31, 2023 and 2022, respectively.

Page | 14

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

Key management personnel also participate in the Company’s share option program (see Note 1 to the unaudited condensed consolidated interim financial statements). The Company recorded compensation to key management personnel the following:

	Three months		Three months		Six months		Six months
	ended		ended		ended		ended
	March 31, 2023		March 31, 2022		March 31, 2023		March 31, 2022
Salaries and benefits	$	256	$	244	$	547	$	511
Stock-based compensation		441		572		678		1,668
Total	$	697	$	816	$	1,225	$	2,179

Off balance sheet arrangements

The Company has no material undisclosed off-balance sheet arrangements that have or are reasonably likely to have, a current or future effect on its results of operations or financial condition.

ACCOUNTING AND DISCLOSURE MATTERS

Financial reporting controls

Internal control over financial reporting

Evaluation of disclosure controls and procedures

Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were not effective due to the material weaknesses in our internal control over financial reporting as reported in Form 40-F for the year ended September 30, 2022, as described below. However, after considering such material weaknesses, and the additional analyses and other procedures that we performed to ensure that our condensed consolidated financial statements included in this Quarterly Report were prepared in accordance with IFRS, our management has concluded that our consolidated financial statements present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods disclosed, in conformity with IFRS.

Management’s report on internal control over financial reporting

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”) (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). The Company's management, under the supervision of the Chief Executive Officer and Chief Financial Officer, and effected by the Company’s board of directors, evaluated the effectiveness of ICFR.  Management has concluded that as of September 30, 2022 and reported in Form 40-F internal control over financial reporting was not effective. Management concluded that the following material weaknesses existed as of March 31, 2023:

● Management did not maintain appropriately designed entity-level controls impacting the control environment, risk assessment procedures, and effective monitoring activities. These deficiencies were attributed to: (i) management has not finalized the design and implementation, or retained appropriate documentation, of formal accounting policies, procedures, and controls across substantially all of the Company’s business processes, (ii) ineffective identification

Page | 15

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

and formal assessment of overall business risks, and (iii) ineffective evaluation and determination as to whether the components of internal control were present and functioning.

● Management did not maintain effective information technology general controls in the areas of user access management and segregation of duties within its systems supporting the Company’s accounting and financial reporting processes. Many of the Company’s manual controls dependent upon the information derived from these information technology systems were also ineffective, as management did not design and implement controls to validate the completeness and accuracy of underlying data utilized in the operation of those manual controls.

● Management did not design and maintain effective controls over certain aspects of its revenue recognition process and related accounts, including controls around the classification of certain contracts as operating leases under IFRS 16.

● Management did not appropriately design and implement management review controls at a sufficient level of precision around complex accounting areas and disclosure including business combinations and forecasts associated with intangible assets.

Remediation Efforts

We have begun the process of, and we are focused on, designing and implementing effective internal controls measures to improve our internal control over financial reporting and remediate the material weaknesses. Our internal control remediation efforts include the following:

● We engaged an outside firm to assist management with (i) reviewing our current processes, procedures, and systems and assessing the design of controls to identify opportunities to enhance the design of controls that would address relevant risks identified by management, and (ii) enhancing and implementing protocols to retain sufficient documentary evidence of operating effectiveness of such controls.  This internal control project is anchored in the framework and criteria established in Internal Control - Integrated Framework, issued by the 2013 Committee of Sponsoring Organizations of the Treadway Commission.

● Continuing to enhance and formalize our accounting, business operations, and information technology policies, procedures, and controls to achieve complete, accurate, and timely financial accounting, reporting and disclosures.

● Designing and implementing controls that address the completeness and accuracy of underlying data used in the performance of controls over accounting transactions and disclosures.

● Enhancing policies and procedures to retain adequate documentary evidence for certain management review controls over certain business processes including precision of review and evidence of review procedures performed to demonstrate effective operation of such controls.

● Finalizing the implementation of entity level controls which are expected to be implemented prior to the end of the year ending September 30, 2023.

Changes in Internal Control over Financial Reporting

As described above, we are in the process of implementing changes to our internal control over financial reporting to remediate the material weaknesses described herein. There have been no other changes in our internal control over financial reporting, during the quarter ended March 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Page | 16

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

Critical accounting estimates

The preparation of financial statements in conformity with IFRS requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities, related disclosures and the reported amounts of revenues and expenses during the periods covered by the financial statements. The Company’s management reviews these estimates, judgments, and assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted prospectively in the period in which the estimates are revised.

Estimates where management has made subjective judgments and where there is significant risk of material adjustments to assets and liabilities in future accounting periods include fair value measurements for financial instruments and share-based transactions, useful lives and impairment of non-financial assets (property and equipment, goodwill, and intangible assets), provision for expected credit losses, fair value measurements for assets and liabilities acquired in business acquisition, and calculation of deferred taxes.

The Company has identified the following accounting policies under which significant judgments, estimates and assumptions are made, where actual results may differ from these estimates under different assumptions and conditions, which may materially affect financial results or the financial position in future periods.

Revenue recognition

Revenues are billed to, and collections are received from both third-party insurers, the largest of which is Medicare, and patients. Because of continuing changes in the health care industry and third-party reimbursement, the consideration receivable from these insurance companies is variable as these billings can be challenged by the payor. Therefore, the amount billed by the Company is reduced by an estimate of the amount that the Company believes is an allowable charge to be ultimately allowed by the insurance contract. The above estimate involves significant judgment including an analysis of past collections and historical modification rates. Management regularly reviews the actual claims approved by the insurance companies, adjusting estimated revenue as required.

Valuation of accounts receivable

The measurement of expected credit losses considers information about past events and current conditions. Forward looking macro-economic factors are incorporated into the risk parameters, such as unemployment rates, inflation, and interest rates. Significant judgments are made in order to incorporate forward-looking information into the estimation of reserves and may result in changes to the provision from period to period which may significantly affect our results of operations.

The Company estimates that a certain portion of receivables from customers may not be collected and maintains a reserve for expected credit losses. The Company evaluates the net realizable value of accounts receivable as of the date of the consolidated statements of financial position. Specifically, the Company considers historical realization data, including current and historical cash collections, accounts receivable aging trends, other operating trends, and relevant business conditions. If circumstances related to certain customers change or actual results differ from expectations, our estimate of the recoverability of receivables could fluctuate from that provided for in our consolidated financial statements. A change in estimate could impact bad debt expense and accounts receivable.

Page | 17

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

Lease liabilities

Estimate of lease term

When the Company recognizes a lease, it assesses the lease term based on the conditions of the lease and determines whether it will extend the lease at the end of the lease contract or exercise an early termination option. As it is not reasonably certain that the extension or early termination options will be exercised, the Company determined that the term of its leases are the lesser of the original lease term or the life of the leased asset. This significant estimate could affect future results if the Company extends the lease or exercises an early termination option.

Incremental borrowing rate

When the Company recognizes a lease, the future lease payments are discounted using the Company’s incremental borrowing rate. This significant estimate impacts the carrying amount of the lease liabilities and the interest expense recorded on the consolidated statement of income (loss) and comprehensive income (loss).

Critical accounting judgments

The following are the critical judgments, apart from those involving estimations, that have been made in the process of applying the Company’s accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements.

Business combinations

In accordance with IFRS 3 – Business Combination (“IFRS 3”), a transaction is recorded as a business combination if the significant assets, liabilities, or activities in addition to property and related mortgage debt assumed constitute a business. A business is defined as an integrated set of activities and assets, capable of being conducted and managed for the purpose of providing a return, lower costs, or other economic benefits. Where there are no such integrated activities, the transaction is treated as an asset acquisition. The estimation of the fair value of the assets and liabilities acquired in an acquisition is subject to judgement concerning estimating market values and predicting future events. These values are uncertain and can materially impact the carrying value of the acquired assets, acquired liabilities, and the amount allocated to goodwill. These estimates and assumptions may change in the future due to uncertain competitive and economic market ‎conditions or changes in business strategies.‎

The process of determining these fair values requires the Company to make estimates and assumptions of a long-term nature regarding discount rates, projected revenues, royalty rates and margins derived from experience, actual operating results, and budgets. These estimates and assumptions may change in the future due to uncertain competitive and economic market conditions or changes in business strategies.

TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS

Page | 18

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

The following table summarizes the Company’s contractual commitments and obligations as of March 31, 2023 (in thousands), which are primarily for debt, leasing of offices and other obligations. The leases have been entered into with terms of between one and ten years, including optional extensions.

			Less than		1-3		4-5		After 5
	Total		1 year		Years		Years		Years
Debt	$	92,810	$	14,981	$	205	$	77,625	$	—
Finance lease obligations		19,928		5,522		10,548		2,535		1,323
Operating leases		76		76		—		—		—
Purchase obligations		—		—		—		—		—
Other obligations		26,323		26,323		—		—		—
Total contractual obligations	$	139,138	$	46,901	$	10,753	$	80,160	$	1,323

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial instrument risk exposure

The Company’s activities expose it to a variety of financial risks: market risk (including price risk, currency risk and interest rate risk), and credit risk. These risks arise from the normal course of operations and all transactions are undertaken to support the Company’s ability to continue as a going concern. Risk management is carried out by management under policies approved by the Board of Directors. Management identifies and evaluates the financial risks in co-operation with the Company’s operating units. The Company’s overall risk management program seeks to minimize potential adverse effects on the Company’s financial performance.

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. Financial instruments that potentially subject the Company to credit risk are primarily cash and accounts receivable. Each subsidiary places its cash with one major financial institution. At times, the cash in the financial institution is temporarily in excess of the amount insured by the Federal Deposit Insurance Corporation. Substantially all accounts receivables are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, directly from patients or for rebates due from manufacturers. Receivables generally are collected within industry norms for third-party payors and from manufacturers. The Company continuously monitors collections from its clients and maintains a reserve for credit losses based upon any specific payor collection issues that are identified and historical experience.

The Company recorded bad debt expense of $2,482,000 and $3,167,000 for the three months ended March 31, 2023, and 2022, respectively. The Company recorded bad debt expense of $4,765,000 and $5,579,000 for the six months ended March 31, 2023, and 2022, respectively. As of March 31, 2023, the Company has 12% of its accounts receivable from Medicare. As this is a federal health insurance program in the United States, there is nominal credit risk associated with these balances.

Currency risk

Currency risk is the risk that the Company will be subject to foreign currency fluctuations in satisfying obligations denominated in foreign currencies. All of the Company’s sales and inventory sold and most all of the Company’s operating expenses are in US dollars. The Company’s common shares are denominated in Canadian dollars. Cash is maintained in both US dollars and Canadian dollars. Consequently, the Company is exposed to foreign currency exchange fluctuations.

Page | 19

MANAGEMENT’S DISCUSSION AND ANALYSIS

March 31, 2023 and 2022

(Tabular dollar amounts expressed in thousands, except per share amounts)

The Company’s objective in managing its foreign currency risk is to minimize its net exposures to foreign currency cash flows by holding most of its cash in US dollars. The Company monitors foreign currency exposures and from time to time could authorize the use of derivative financial instruments such as forward foreign exchange contracts to economically hedge a portion of foreign currency fluctuations.

Based on the above net exposure at the three months ended March 31, 2023, depreciation, or appreciation of the US dollar against the Canadian dollar could result in a significant effect on net income or loss. The Company has not employed any foreign currency hedging programs.

Interest rate risk

Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s Senior Credit Facility, which an outstanding principal balance of $81,802,000 as of March 31, 2023, bears interest at variable rates that will re-price within one month.

RISK FACTORS

We have disclosed the risk factors affecting our business, financial condition, and operating results in the section entitled “Risk Factors” in our Annual Report for the year ended September 30, 2022. There have been no material changes from the risk factors previously disclosed.

Page | 20

EX-99.3

Exhibit 99.3

FORM 52-109F2

CERTIFICATION OF INTERIM FILINGS

FULL CERTIFICATE

I, Gregory Crawford, as Chief Executive Officer of Quipt Home Medical Corp., certify the following:

1.  Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Quipt Home Medical Corp. (the “issuer”) for the interim period ended March 31, 2023.

2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

5.1 Control framework:  The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is COSO Internal Control Integrated Framework.

5.2 N/A

5.3 Limitation on scope of design:  The issuer has disclosed in its interim MD&A

(a) the fact that the issuer’s other certifying officer(s) and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of

(iii)a business that the issuer acquired not more than 365 days before the last day of the period covered by the interim filings; and

(b) summary financial information about the proportionately consolidated entity, special purpose entity or business that the issuer acquired that has been proportionately consolidated or consolidated in the issuer’s financial statements.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on October 1, 2022 and ended on March 31, 2023 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

Date: May 15, 2023

/s/Gregory Crawford

Gregory Crawford

Chief Executive Officer

EX-99.4

Exhibit 99.4

FORM 52-109F2

CERTIFICATION OF INTERIM FILINGS

FULL CERTIFICATE

I, Hardik Mehta, as Chief Financial Officer of Quipt ‎Home Medical Corp., certify the following:

1.  Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Quipt Home Medical Corp. (the “issuer”) for the interim period ended March 31, 2023.

2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility:  The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

5. Design:  Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

5.1 Control framework:  The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is COSO Internal Control Integrated Framework.

5.2 N/A

5.3 Limitation on scope of design:  The issuer has disclosed in its interim MD&A

(a) the fact that the issuer’s other certifying officer(s) and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of

(iii) a business that the issuer acquired not more than 365 days before the last day of the period covered by the interim filings; and

(b) summary financial information about the proportionately consolidated entity, special purpose entity or business that the issuer acquired that has been proportionately consolidated or consolidated in the issuer’s financial statements.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on October 1, 2022 and ended on March 31, 2023 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

Dated: May 15, 2023

(signed) “Hardik Mehta”

Hardik Mehta

Chief Financial Officer

EX-99.5

Exhibit 99.5

QUIPT HOME MEDICAL REPORTS RECORD SECOND QUARTER FISCAL 2023 FINANCIAL RESULTS POSTING REVENUE GROWTH OF 73% AND ADJUSTED EBITDA GROWTH OF 86%

POSTS STRONG ADJUSTED EBITDA MARGIN OF 22.5% AND SEQUENTIAL ORGANIC GROWTH OF 2.5%

Cincinnati, Ohio – May 15, 2023 – Quipt Home Medical Corp. (the “Company” or “Quipt") (NASDAQ: QIPT; TSXV: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its second quarter fiscal 2023 financial results and operational highlights. These results pertain to the three and six months ended March 31, 2023, and are reported in U.S. Dollars.

Quipt will host its Earnings Conference Call on Tuesday, May 16, 2023, at 10:00 a.m. (ET). The dial-in number is 1 (800) 319-4610 or 1 (604) 638-5340. The live audio webcast can be found on the investor section of the Company’s website through the following link: www.quipthomemedical.com.

Financial Highlights:

● Revenues for fiscal Q2 2023 were $58.1 million compared to $33.6 million for fiscal Q2 2022, representing a 73% increase year-over-year.

o Compared to Q1 2023, the Company experienced very strong sequential organic growth of 2.5%.

o The Company anticipates organic growth continuing to meet or surpass historical levels of 8%-10% annually as calendar 2023 progresses.

● Revenues for the six months ended March 31, 2023, increased to $98.9 million, representing an increase of 56.8% from the six months ended March 31, 2022.

● Recurring Revenue (defined below) for fiscal Q2 2023 continues to be strong and exceeded 78% of revenues.

● Adjusted EBITDA (defined below) for fiscal Q2 2023 was $13.1 million (22.5% of revenues), compared to Adjusted EBITDA for fiscal Q2 2022 of $7.0 million (21.0% of revenues), representing an 86% increase year-over-year. The Company expects to continue to see strong margin performance throughout fiscal 2023.

● Adjusted EBITDA for the six months ended March 31, 2023, increased to $22.1 million, representing an increase of 69% from the six months ended March 31, 2022, and represented 22.3% of revenues.

● For fiscal Q2 2023, bad debt expense was at 4.2% of revenues compared to 9.4% in fiscal Q2 2022. This decrease is primarily due to improved collections and is attributable to the Company’s ability to scale and add revenue through add-on acquisitions without compromising billing capabilities.

● Cash flow from continuing operations was $14.8 million for the six months ended March 31, 2023, compared to $11.8 million for the six months ended March 31, 2022.

● The Company reported $2.1 million of cash on hand and $28 million available on its senior credit facility as of March 31, 2023, with $7 million available on the revolving line of credit and $21 million available on the delayed-draw term loan.

o Subsequent to March 31, 2023, on April 25, 2023, the Company completed a bought deal public offering and concurrent private placement of common shares for net proceeds of $28.9 million (the “April Offering”). The Company’s pro forma balance sheet, taking into consideration the April Offering, contains $18 million of cash and $41 million available on its senior credit facility.

● The Companymaintains a conservative balance sheet with net debt to Adjusted EBITDA of 1.5x on a pro forma basis, taking into consideration the April Offering.

Operational Highlights:

● The Company’s customer base increased 76% year over year to 137,748 unique patients served in fiscal Q2 2023, compared to 78,273 unique patients in fiscal Q2 2022.

● Compared to 118,878 unique set-ups/deliveries in fiscal Q2 2022, the Company completed 198,101 unique set-ups/deliveries in fiscal Q2 2023, an increase of 67%. There were 106,486 respiratory resupply set-ups/deliveries during fiscal Q2 2023 compared to 50,713 during fiscal Q2 2022, an increase of 110%, which the Company credits to its continued use of technology and centralized intake processes.

● The Company’s product mix is 79% respiratory as of March 31, 2023.

● The Company continues to experience robust demand for respiratory equipment, such as oxygen concentrators, ventilators, as well as the CPAP resupply and other supplies business.

● The Company has expanded its sales reach, which now spans across 26 U.S. states with the addition of experienced sales personnel.

Subsequent Highlights:

● On April 4, 2023, the Company announced the execution of an additional national insurance contract with a top five health insurer based on membership in the United States¹. This represents the second national insurance contract the Company has signed since April 2022.

● On May 2, 2023, the Company announced that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate its listing from the TSX Venture Exchange (the “TSXV”) to the TSX. Final approval of the listing is subject to the Company meeting certain customary conditions required by the TSX. The Company is working diligently to satisfy such listing conditions. Further details and a timeline for graduation will be announced in due course.

Management Commentary on Q2 2023:

“We are thrilled to announce robust financial results that have come in ahead of expectations for the second quarter of fiscal 2023 and are delighted to report that we continue to observe significant and continued momentum throughout the organization. This past quarter has seen our supply chain return to normal, stronger organic growth, an increase in our Adjusted EBITDA margin, and the seamless integration of our largest acquisition,Great Elm, to date. We are extremely delighted that our team’s focus on operational excellence has produced such outstanding results and believe that our continued focus therein will yield increased margins as we move into the second half of 2023. Additionally, we have a strong acquisition pipeline and will continue to use our tried-and-true approach to integration and our focused acquisition strategy to execute on our long-term vision,” said CEO and Chairman Greg Crawford.

“By focusing on areas with a high prevalence of chronic obstructive pulmonary disease (COPD), we were able to expand our patient-centric ecosystem across the United States. Our success is a direct result of our dedication to improving patient care by offering a full range of respiratory and equipment solutions. As the need for efficient and timely home health care increases and in an effort to help ease the strain on the traditional healthcare system, we take our role as a major provider of these services very seriously and will always focus on providing superior patient care. Due to favorable demographic trends, the bullish regulatory environment, the continued strong demand for respiratory equipment, and our consistent operational performance across the entire organization, I truly believe that Quipt is in the strongest position it has ever been.”

Chief Financial Officer Hardik Mehta added, “We have a lot to be proud of because of our outstanding financial and operational performance in the second quarter of fiscal 2023. This is a remarkable accomplishment for the team because we exceeded our revenue and Adjusted EBITDA targets, raised our Adjusted EBITDA margin to 22.5%, and showed excellent 2.5% sequential organic growth. We also announced the completion of our largest acquisition to date at the start of the year, and I am happy to report that integration has gone very well and that we were able to realize the $2 million in annualized cost savings and synergies previously anticipated roughly a quarter ahead of schedule. Moreover, we closed a bought deal offering and concurrent private placement after the quarter ended to further fortify our already strong balance sheet, giving us more room to carry out our aggressive strategic expansion plan. This success has allowed us to maintain a very low net leverage ratio of 1.5x and a high degree of financial flexibility. We think we are in an excellent position to take decisive action as soon as the right opportunity presents itself.”

ATM:

Quipt is also pleased to announce that it has filed a prospectus supplement establishing a new At-the-Market equity program (the “ATM”). Canaccord Genuity (“Canaccord”) and Beacon ‎Securities Limited (“Beacon” and together with Canaccord, the “Agents”), ‎are acting as agents for the ATM . The ATM will allow the Company to offer for sale and issue up to $40 million (or the equivalent in Canadian dollars) of common shares of the Company (the “Common Shares”) from time to time, at the Company’s discretion. Any sales of Common Shares under the ATM will be made through "at-the-market distributions" as defined in Regulation 44-102 respecting Shelf Distributions, including sales made directly on the TSXV (or the TSX if, as previously announced, the Company successfully graduates to the TSX), the NASDAQ Capital Market or on any other trading market for the Common Shares in Canada or the United States. The Common Shares will be distributed at the market prices prevailing at the time of the sale, and, as a result, prices may vary between purchasers and during the period of the ATM. The Company is not obligated to make any sales of Common Shares under the ATM.

The Company has adequate liquidity resources and does not currently intend to use the ATM, however the Company believes it is prudent to have this program in place in order to access capital to ensure the Company maintains sufficient liquidity and capital resources in the future. The Company intends to use net proceeds from the ATM, if any, for repayment of debt, potential future ‎acquisitions, working capital and general corporate purposes.

Distributions of the Common Shares through the ATM will be made pursuant to the terms of an equity distribution agreement dated May 15, 2023 (the “Distribution Agreement”) by and among the Company and the Agents, pursuant to which the Company may distribute Common Shares under the ATM from time to time through the Agents, in accordance with the terms of the Distribution Agreement.

A prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated November 11, 2021 (the “Base Shelf Prospectus”) has been filed with the securities commissions or securities regulatory authorities in each of the provinces of Canada, and a prospectus supplement, dated May 15, 2023, related to the ATM (the “U.S. Prospectus Supplement”) has also been filed  with the United States Securities and Exchange Commission (the “SEC”) as part of the Company's registration statement Form F-10 (File No. 333-26036) (as amended, the “Registration Statement”) under the United States/Canada multijurisdictional disclosure system. The Prospectus Supplement, the Base Shelf Prospectus, the U.S. Prospectus Supplement and the Registration Statement contain important detailed information about the Company and the ATM.

Prospective investors should read the Prospectus Supplement, the Base Shelf Prospectus, the U.S. Prospectus Supplement, and the Registration Statement and the other documents the Company has filed for more complete information about the Company and the ATM before making an investment decision.

The Prospectus Supplement filed in Canada (together with the related Base Shelf Prospectus) and the Distribution Agreement will be available on SEDAR at www.sedar.com. The U.S. Prospectus Supplement and the Distribution Agreement filed in the United States (together with the Registration Statement) will be available on the SEC’s website on EDGAR at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction. The securities being offered and the contents of this press release have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon by the accuracy or adequacy of the Prospectus Supplement, the Base Shelf Prospectus, the U.S. Prospectus Supplement or the Registration Statement.

Management Commentary on ATM:

“Given our sustained strong expansion and future goals, the Company is dedicated to diversifying its sources of capital to fund its long-term acquisition strategy,” said Greg Crawford, CEO of Quipt. “The ATM will allow the Company to opportunistically raise equity in a more timely and cost-effective manner.”

ABOUT QUIPT HOME MEDICAL CORP.

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.

Reader Advisories

There can be no assurance that any of the potential acquisitions in the Company’s pipeline or in negotiations will ‎be completed as proposed or at all and no definitive agreements have been executed. Completion of any ‎transaction will be subject to applicable director, shareholder, and regulatory approvals.‎

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of ‎the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.‎

Forward-Looking Statements

Certain statements contained in this press release constitute "forward-looking information" as such term is ‎‎‎defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", ‎‎‎‎"will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect", "outlook", and similar expressions ‎‎as ‎they relate to the Company, including: the Company anticipating organic growth continuing to meet or surpass historical levels of 8-10% annually as calendar 2023 progresses; the Company expecting to continue to see strong margin performance throughout fiscal 2023; the impact the execution of this national insurance contract will have on the Company, if any; the Company satisfying TSX listing conditions; the Company graduating to the TSX and the timing of graduation; the Company believing that its continued focus on operational excellence will yield increased margins as the Company moves into the second half of 2023; the timing and completion of the ATM; and the expected use of proceeds

of the ATM; are intended to ‎identify forward-looking information. All statements ‎other than statements of ‎historical fact may be forward-‎looking information. Such statements reflect the ‎Company's current views and ‎intentions with respect to future ‎events, and current information available to the ‎Company, and are subject to ‎certain risks, uncertainties and ‎assumptions, including: the ‎Company successfully identified, ‎negotiating and completing additional acquisitions;that the ATM will be completed, in whole or part, and on favourable terms; and that the proceeds from the ATM will be utilized by the Company as currently expected. Many factors could cause the actual ‎results, ‎performance or achievements that may be expressed ‎or implied by such forward-looking information to ‎vary from ‎those described herein should one or more of these ‎risks or uncertainties materialize. Examples of such ‎risk factors ‎include, without limitation: risks related to credit, market ‎‎(including equity, commodity, foreign exchange and interest ‎rate), ‎liquidity, operational (including technology ‎and infrastructure), reputational, insurance, strategic, ‎regulatory, legal, ‎environmental, and capital adequacy; the ‎general business and economic conditions in the regions ‎in which the ‎Company operates; the ability of the ‎Company to execute on key priorities, including the successful ‎completion of ‎acquisitions, business retention, and ‎strategic plans and to attract, develop and retain key ‎executives; difficulty ‎integrating newly acquired businesses; ‎the ability to implement business strategies and ‎pursue business opportunities; low profit ‎market segments; ‎disruptions in or attacks (including cyber-attacks) on ‎the Company's information technology, ‎internet, network ‎access or other voice or data communications systems or ‎services; the evolution of various types ‎of fraud or other ‎criminal behavior to which the Company is exposed; the ‎failure of third parties to comply with ‎their obligations to ‎the Company or its affiliates; the impact of new and ‎changes to, or application of, current ‎laws and regulations; ‎decline of reimbursement rates; dependence on few ‎payors; possible new drug discoveries; a ‎novel business model; ‎dependence on key suppliers; granting of permits ‎and licenses in a highly regulated ‎business; the overall difficult ‎litigation environment, including in the U.S.; ‎increased competition; changes in ‎foreign currency rates; increased ‎funding costs and market volatility due to ‎market illiquidity and competition for ‎funding; the availability of funds ‎and resources to pursue operations; ‎critical accounting estimates and changes ‎to accounting standards, policies, ‎and methods used by the Company; ‎the occurrence of natural and unnatural ‎catastrophic events and claims ‎resulting from such events; and risks ‎related to COVID-19 including various ‎recommendations, orders and ‎measures of governmental authorities to try ‎to limit the pandemic, including travel ‎restrictions, border closures, ‎non-essential business closures, quarantines, ‎self-isolations, shelters-in-place and social distancing, ‎disruptions ‎to markets, economic activity, financing, ‎supply chains and sales channels, and a deterioration of general ‎economic ‎conditions including a possible ‎national or global recession; as well as those risk factors discussed or ‎referred to ‎in the Company’s disclosure ‎documents filed with United States Securities and Exchange Commission ‎and ‎available at www.sec.gov, and with ‎the securities regulatory authorities in certain provinces of Canada and ‎‎available at www.sedar.com. Should any ‎factor affect the Company in an unexpected manner, or should ‎‎assumptions underlying the forward-looking ‎information prove incorrect, the actual results or events may differ ‎‎materially from the results or events predicted. ‎Any such forward-looking information is expressly qualified in its ‎‎entirety by this cautionary statement. Moreover, ‎the Company does not assume responsibility for the accuracy or ‎‎completeness of such forward-looking ‎information. The forward-looking information included in this press release ‎‎is made as of the date of this press ‎release and the Company undertakes no obligation to publicly update or revise ‎‎any forward-looking information, ‎other than as required by applicable law‎.‎

Non-GAAP Measures

This press release refers to “Recurring Revenue” and “Adjusted EBITDA”, which are non-‎GAAP and non-IFRS financial measures that do not have standardized meanings prescribed by GAAP or IFRS. The ‎Company’s presentation of these financial

measures may not be comparable to similarly titled measures used by ‎other companies. These financial measures are intended to provide additional information to investors concerning ‎the Company’s performance.‎

Recurring Revenue for Quipt for fiscal Q2, 2023, as used in this press release is calculated as rentals of medical equipment of $24.5 million plus sales of respiratory resupplies of $20.6 million for a total of $45.1 million, divided by total revenues of $58.1 million, or 78%.

EBITDA is defined as net income (loss), and adding back interest expense, net, depreciation and amortization, and provision (benefit) for income taxes. Adjusted EBITDA is defined as EBITDA and adding back stock-based compensation, acquisition-related costs, loss on foreign currency transactions, loss on extinguishment of debt, other income from government grant, and change in fair value of debentures. ‎EBITDA and Adjusted EBITDA are non-IFRS measures that the Company uses as an indicator of financial health and exclude ‎several items which may be useful in the consideration of the financial condition of the Company.The following table shows our Non-IFRS measures (EBITDA and Adjusted EBITDA) reconciled to our net income (loss) for the ‎following indicated periods‎ (in $millions)‎:‎

	Three		Three		Six		Six
	months		months		months		months
	ended March		ended March		ended March		ended March
	31, 2023		31, 2022		31, 2023		31, 2022
Net income (loss)	$	(0.7)	$	5.0	$	(0.4)	$	2.9
Add back:
Depreciation and amortization		9.6		5.5		16.4		10.5
Interest expense, net		2.0		0.5		2.7		1.0
Provision for income taxes		—		0.1		0.3		0.3
EBITDA		10.9		11.1		19.0		14.7
Stock-based compensation		1.3		1.2		1.9		3.3
Acquisition-related costs		0.9		0.2		1.2		0.3
Loss on foreign currency transactions		—		0.1		—		0.1
Loss on extinguishment of debt		—		—		—		—
Other income from government grant		—		(4.3)		—		(4.3)
Change in fair value of debentures and warrants		—		(1.3)		—		(1.1)
Adjusted EBITDA	$	13.1	$	7.0	$	22.1	$	13.1

For further information please visit our website at www.Quipthomemedical.com, or contact:‎

Cole Stevens

VP of Corporate Development

Quipt Home Medical Corp.‎

‎859-300-6455‎

cole.stevens@myquipt.com

Gregory Crawford

Chief Executive Officer

Quipt Home Medical Corp.‎

‎859-300-6455‎

investorinfo@myquipt.com

¹https://www.valuepenguin.com/largest-health-insurance-companies#member